Cannabis - Cannabinoid - Hyperemesis Syndrome - Acute Intoxication - Haloperidol
EMPOWERING PHYSICIANS WITH EVIDENCE-BASED CONTENT
 

Home > Browse Topics

Cannabinoids: Emerging Topics in Use and Abuse

Cannabis - Cannabinoid - Hyperemesis Syndrome – Acute Intoxication – Haloperidol

Cannabinoids: Emerging Topics in Use and Abuse

Facebook for Cannabis - Cannabinoid - Hyperemesis Syndrome – Acute Intoxication – Haloperidol Twitter for Cannabis - Cannabinoid - Hyperemesis Syndrome – Acute Intoxication – Haloperidol Linkedin for Emergency Cannabis - Cannabinoid - Hyperemesis Syndrome – Acute Intoxication – Haloperidol

  About This Issue

As the use of cannabinoids increases, so have ED presentations of patients with acute intoxication and cannabinoid hyperemesis syndrome. This issue reviews the latest evidence on recognizing and managing patients with emergent conditions related to cannabinoid use, including:

•  An overview of the pathophysiology of cannabinoids.
•  Current evidence on the common and uncommon clinical findings associated with cannabinoid use: neurologic, psychiatric, cardiovascular, renal, metabolic, oral, and ophthalmologic.
•  How synthetic cannabinoids can be similar to - and different from - natural and "medical" cannabis products.
•  How to determine when laboratory testing is indicated, and when it is not.
•  A look at the current evidence on cannabinoid hyperemesis syndrome, including some emerging management strategies for this commonly misdiagnosed condition.
•  The latest information on the legal and FDA approval status of cannabinoid drugs.

  Issue Information

Author: Mollie V. Williams, MD

Peer Reviewers: Joseph Habboushe, MD, MBA; Nadia Maria Shaukat, MD, RDMS, FACEP

Publication Date: August 1, 2018

CME Expiration Date: August 1, 2021

CME Credits: 4 AMA PRA Category 1 CreditsTM, 4 ACEP Category I Credits, 4 AAFP Prescribed Credits, 4 AOA Category 2A or 2B Credits. Included as part of the 4 credits, this CME activity is eligible for 1 Behavioral Health credit and 2 Pharmacology credits in pharmacotherapy, subject to your state and institutional approval.

PubMed ID: 30020736

  Issue Features
  Table of Contents
  1. Abstract
  2. Case Presentations
  3. Introduction
  4. Critical Appraisal of the Literature
  5. Etiology and Pathophysiology
    1. Synthetic Cannabinoids
    2. Current Indications for Cannabinoids
    3. Routes of Administration
    4. Clinical Findings Associated With Acute Use
      1. Neurologic Effects
      2. Psychiatric Effects
      3. Cardiovascular Effects
      4. Pulmonary Effects
      5. Renal Effects
      6. Metabolic Effects
      7. Oral/Dental Effects
      8. Ophthalmologic Effects
      9. Cannabinoid Hyperemesis Syndrome
    5. Withdrawal
  6. Differential Diagnosis
  7. Prehospital Care
  8. Emergency Department Evaluation
    1. History
    2. Physical Examination
  9. Diagnostic Studies
    1. Laboratory Testing
    2. Electrocardiogram
    3. Imaging
  10. Treatment
    1. Treatment for Acute Cannabis and Synthetic Cannabinoid Toxicity
    2. Treatment for Cannabinoid Hyperemesis Syndrome
  11. Special Populations
    1. Pediatric Patients
    2. Pregnant Women
  12. Controversies and Cutting Edge
    1. Legal Status of Cannabis/Cannabinoids
    2. Haloperidol for Cannabinoid Hyperemesis Syndrome Treatment
    3. Capsaicin for Cannabinoid Hyperemesis Syndrome Treatment
  13. Disposition
  14. Summary
  15. Risk Management Pitfalls for Management of Acute Cannabis Use
  16. Key Points
  17. Time and Cost-Effective Strategies
  18. Case Conclusions
  19. Clinical Pathway for Emergency Department Management of Cannabinoid Hyperemesis Syndrome
  20. Tables
    1. Table 1. Main Constituents of Cannabis Sativa
    2. Table 2. Peak Plasma Concentration Times of THC via Various Routes of Administration
    3. Table 3. Symptoms and Findings for Clinical Diagnosis of Cannabinoid Hyperemesis Syndrome
    4. Table 4. Differential Diagnosis for Suspected Cannabis Intoxication
    5. Table 5. Differential Diagnosis of Intractable Vomiting
    6. Table 6. Drugs Implicated in False-Positive Cannabinoid Screening
  21. References

 

Abstract

Despite current legal and medical controversies surrounding cannabinoids, it is a fact that emergency departments are seeing an increasing number of patients presenting with symptoms associated with the use of these drugs. This review outlines the pathophysiology of cannabinoids, the potential clinical findings associated with their use, and the current evidence for best-practice management of patients who present to the emergency department with signs of acute intoxication and chronic use. Differences between natural and synthetic cannabinoids are discussed, along with the latest evidence for diagnosing and managing patients presenting with the intractable vomiting of cannabinoid hyperemesis syndrome. Emerging treatments for cannabinoid hyperemesis syndrome are presented, including hot water bathing, early haloperidol administration, and topical capsaicin, in addition to an update on the legal status of medical cannabinoid substances.

 

Case Presentations

A 25-year-old woman is found at a bus stop by bystanders after a “syncopal” episode. The patient was seen stumbling as she attempted to board a bus, and she exhibited an apparent lack of coordination. Upon arrival to the ED, the patient states that she feels fine, and “everything is OK. I only smoked a little pot.” On evaluation, the patient is seated comfortably on the stretcher and is pleasant during the history and physical examination. She reports a past medical history of anxiety, but nods off during questioning. Her vital signs are: heart rate of 107 beats/min; respiratory rate, 16 breaths/min; blood pressure, 135/77 mm Hg while seated; temperature, 37.2°C; and oxygen saturation, 98% on room air. Upon examination, you note the patient has conjunctival injection, dry oral mucosa, and tachycardia, but an otherwise unremarkable examination, including neurologic assessment. At the end of your encounter, the patient says “thanks,” and requests to leave the ED for work. You wonder whether she should have a syncope workup and be kept in observation. Because you suspect marijuana intoxication, you wonder whether she should be advised to not go to work.

As you proceed to log into the EMR, EMS arrives with a 17-year-old previously healthy boy with tachycardia and violent behavior. The patient’s mother called 911 because she found him behaving strangely when she arrived home from work. The patient appears very agitated and is unable to remain seated on the stretcher during the clinical encounter. The patient reports chest pain and palpitations. His vital signs are: heart rate, 146 beats/min; blood pressure, 169/99 mm Hg; respiratory rate, 21 breaths/min; temperature, 38°C; oxygen saturation, 100% on room air; and fingerstick glucose, 65 mg/dL. Could this be an overdose or toxic ingestion? What further diagnostic tests and/or interventions should be initiated, if any?

Toward the end of your shift, a 52-year-old man writhing in pain and retching repeatedly is wheeled in by the triage nurse. He has made frequent visits to the ED over the past 2 years for abdominal pain and intractable vomiting. The patient reports that his symptoms have become so severe over the last 2 months that he has had to visit the ED frequently to gain relief, and he has lost approximately 10 pounds over the last 4 weeks. Within the last 2 months, he notes that he has had multiple blood draws in the ED and by his primary care doctor, ultrasounds of the abdomen and kidneys, 2 CT scans of the abdomen/pelvis, and an esophagogastroduodenoscopy, revealing chronic gastritis, with no evidence of peptic ulcer disease or Helicobacter pylori. The patient states that his symptoms are usually very difficult to control, and he is frequently admitted and later discharged home with a diagnosis of gastritis, only to return again the next month. His vital signs are unremarkable. You develop a differential for intractable vomiting and ask the patient a key question that leads to the diagnosis…

 

Introduction

According to the National Conference of State Legislatures, as of June 2018, there are 31 states, the District of Columbia, and 2 United States territories possessing state and local-level laws allowing for the use of cannabis in medicinal and/or recreational formulations.1 As of 2015, marijuana maintains the highest lifetime, past-year, and past-month use of all illicit drugs used within the United States and within all age categories. There are currently 22.2 million past-month users of marijuana among persons aged 12 or older, followed by pain relievers (3.78 million), cocaine (1.88 million), and tranquilizers (1.87 million).2,3 Recent studies in Colorado, where both medicinal and recreational marijuana use have been decriminalized and later legalized, have revealed a nearly 2-fold increase in the prevalence of emergency department (ED) visits and hospitalizations that the authors suggest may be due to marijuana exposure.4,5

Despite controversial beliefs that cannabis has no accepted medical use,1,6 its use for medical purposes has been documented as far back as 600 BC, from its suspected origin in West and Central Asia.7 Throughout its long history, cannabis use for medicinal purposes has been documented in Sanskrit, Hindi, Greek, and Western European literature for the treatment of diseases such as pretreatment for migraines, seizure disorders, tetany/spastic disorders, rheumatoid disorders, trigeminal neuralgia, asthma, and the inability to sleep.7,8 Currently, cannabis and cannabinoids are being used in the treatment of chronic pain syndromes, complications of multiple sclerosis and paraplegia, weight loss due to appetite suppression in HIV/AIDS, chemotherapy-induced nausea and vomiting, and many neuropsychiatric disorders, including seizure disorder. Nonetheless, there is an absence of high-quality evidence to support the use of cannabis and cannabinoids for any of these indications.9

To date, the use of cannabis for all purposes has been largely limited by the United States Department of Justice Drug Enforcement Administration (DEA) listing of cannabis as a Schedule I substance6, rendering its use illegal at the federal level. The DEA designation further hinders the ability both to conduct research at any level, as well as any possibility of obtaining funding from the federal government for such research.7 There is much variation in legislation at both the state and local levels of government concerning dispensaries, retail sales, and the various formulations of cannabis-containing products.1

The lack of federal regulations on the chemical content of available cannabis leads to much product variation. This variation may increase the number of patients presenting to the ED due to accidental overdose leading to toxicity.5

This issue of Emergency Medicine Practice reviews the emerging evidence on the basic pathophysiology of the endocannabinoid system, describes common presentations of acute intoxication due to marijuana and synthetic cannabinoids, identifies common characteristics and distinguishing factors of cannabinoid hyperemesis syndrome (CHS), and outlines the current and emerging treatment and disposition practices for CHS.

 

Critical Appraisal of the Literature

A search of PubMed and the Cochrane Database of Systematic Reviews was conducted for articles published from 1950 to 2018 using the following search terms: cannabis, marijuana, synthetic cannabinoids, cannabimimetic, and cannabinoid hyperemesis syndrome. The PubMed search produced numerous retrospective studies, predominantly case reports, case series, case reviews, systematic reviews, and meta-analyses. There were few randomized prospective studies identifying the medical applications for cannabis use, the adverse effects of cannabis and synthetic cannabis use, and the current options used in the treatment of acute cannabis/synthetic cannabinoid intoxication and CHS. The majority of literature available within the Cochrane Database evaluates the role of cannabis in the treatment of various chronic disorders; it offers no information on the adverse effects associated with acute cannabis intoxication. Additional historical information was obtained from book chapters and materials available via the Internet (such as government documents). The National Guideline Clearinghouse provided no resources for cannabis intoxication and cannabis-related disorders.

 

Risk Management Pitfalls for Management of Acute Cannabis Use

1. “The patient just smoked K2/Spice. He complains only of flank pain with a normal urinalysis, he doesn’t need any labs. He can sit in the corner until he is sober.”

Patients presenting to the ED after smoking synthetic cannabinoids will likely present to the ED with neuropsychiatric and cardiovascular complaints. However, patients presenting with abdominal or flank pain, and/or nausea and vomiting after the acute use of cannabis/ cannabinoids may be susceptible to acute kidney injury, and should have further diagnostic testing performed; in this case, urinalysis, basic metabolic profile (for BUN and creatinine), and CPK levels if rhabdomyolysis is suspected.

3. “This patient always comes in for intractable nausea and vomiting due to smoking cannabis. His abdomen is rigid and diffusely tender, but I don’t think he needs any further evaluation.”

Patients presenting to the ED due to CHS should have a full evaluation in the ED if they present with signs and/or symptoms consistent with intra-abdominal pathology. Patients with an “acute” abdomen should have a full evaluation, including radiologic testing, despite the history of CHS.

10. “The 11-year-old patient with a history of cyclical vomiting syndrome currently prescribed pantoprazole by her family physician presented to the ED due to nausea and vomiting. I ordered a urinalysis, urine pregnancy, and urine toxicology test as part of the evaluation and found the urine positive for THC. I considered calling child protective services.”

Patients may have a false-positive test for THC after using medications such as pantoprazole, ibuprofen, and efavirenz. Before alerting authorities in response to what may be a false-positive test, with its potential ramifications to the child and the family, consider the patient's medication history.

 

Tables

Table 3. Symptoms and Findings for Clinical Diagnosis of Cannabinoid Hyperemesis Syndrome76,78

Among patients reporting years-long, regular, frequent cannabis use:
  • Major Clinical Symptoms
    • Severe nausea and vomiting
    • Cyclical, recurrent vomiting over months
  • Supporting Symptoms/Findings
    • Compulsive bathing in hot water, resulting in relief of symptoms
    • Age < 50 years
    • Weight loss > 5 kg
    • Colicky abdominal pain; normal bowel habits
    • No evidence of gall bladder or pancreatic inflammation
    • Morning predominance of symptoms
    • Resolution of symptoms with cessation of cannabis use

 

References

Evidence-based medicine requires a critical appraisal of the literature based upon study methodology and number of subjects. Not all references are equally robust. The findings of a large, prospective, randomized, and blinded trial should carry more weight than a case report.

To help the reader judge the strength of each reference, pertinent information about the study, such as the type of study and the number of patients in the study is included in bold type following the references, where available. In addition, the most informative references cited in this paper, as determined by the author, are highlighted.

  1. National Conference of State Legislatures. State medical marijuana laws. 6/27/2018. Available at: http://www.ncsl.org/research/health/state-medical-marijuana-laws.aspx. Accessed July 10, 2018. (Legislative support organization website)
  2. Azofeifa A, Mattson ME, Schauer G, et al. National estimates of marijuana use and related indicators - National Survey on Drug Use and Health, United States, 2002-2014. MMWR Surveill Summ. 2016;65(11):1-28. (US government statistical report)
  3. Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: results from the 2015 National Survey on Drug Use and Health: detailed tables. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2016:178-182. (US Government report)
  4. Kim HS, Anderson JD, Saghafi O, et al. Cyclic vomiting presentations following marijuana liberalization in Colorado. Acad Emerg Med. 2015;22(6):694-699. (Cross-sectional study; 36 patients)
  5. Kim HS, Monte AA. Colorado cannabis legalization and its effect on emergency care. Ann Emerg Med. 2016;68(1):71-75. (Literature review; 21 studies)
  6. United States Drug Enforcement Administration. Title 21 United States Code (USC) Controlled Substances Act. Vol 1308. Springfield, VA: US Department of Justice; 1973. (US Government report)
  7. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: What a long strange trip it’s been …. Headache. 2015;55(6):885-916. (Review)
  8. Thomas B, ElSohly M. The Analytical Chemistry of Cannabis. 1st Edition. Amsterdam, Netherlands: Elsevier; 2016. (Textbook)
  9. Whiting PF, Wolff RF, Deshpande S, et al. Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015;313(24):2456-2473. (Retrospective chart review; 4 cases)
  10. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry. 2001;178:101-106. (Review)
  11. Le Foll B, Tyndale RF. Cannabinoids: friend or foe? Clin Pharmacol Ther. 2015;97(6):528-531. (Review)
  12. Bloomfield MA, Ashok AH, Volkow ND, et al. The effects of Δ(9)-tetrahydrocannabinol on the dopamine system. Nature. 2016;539(7629):369-377. (Review)
  13. Fan P. Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol. 1995;73(2):907-910. (Experimental research)
  14. Xiong W, Koo BN, Morton R, et al. Psychotropic and nonpsychotropic cannabis derivatives inhibit human 5-HT(3A) receptors through a receptor desensitization-dependent mechanism. Neuroscience. 2011;184:28-37. (Experimental research)
  15. Iannotti FA, Hill CL, Leo A, et al. Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability. ACS Chem Neurosci. 2014;5(11):1131-1141. (Experimental research)
  16. Center for Behavioral Health Statistics and Quality. The DAWN Report: drug-elated emergency department visits involving synthetic cannabinoids. Rockville, MD: US Substance Abuse and Mental Health Services Administration; 2012. (US Government report)
  17. Cooper ZD. Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatry Rep. 2016;18(5):52. (Review)
  18. Brents LK, Prather PL. The K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev. 2014;46(1):72-85. (Review)
  19. Moeller KE, Kissack JC, Atayee RS, et al. Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clin Proc. 2017;92(5):774-796. (Review)
  20. United States Drug Enforcement Administration. Schedules of controlled substances: temporary placement of four synthetics cannabinoids into Schedule I. Vol 79. Washington DC: United States Drug Enforcement Administration; 2014. (US Government report)
  21. Russo EB. Current therapeutic cannabis controversies and clinical trial design issues. Front Pharmacol. 2016;7:309. (Review)
  22. National Institute on Drug Abuse. Synthetic cannabinoids. 2015. Available at: www.drugabuse.gov/publications/drugfacts/synthetic-cannabinoids. Accessed July 10, 2018. (US Government report)
  23. Samaan J, Ferrer GF, Akinyemi B, et al. Synthetic cannabis overdose and withdrawal in a young adult: a case report, commentary on regulation, and review of the literature. Case Rep Psychiatry. 2016;2016:3640549. (Literature review and case report; 1 patient)
  24. Riederer AM, Campleman SL, Carlson RG, et al. Acute poisonings from synthetic cannabinoids - 50 U.S. Toxicology Investigators Consortium Registry Sites, 2010-2015. MMWR Morb Mortal Wkly Rep. 2016;65(27):692-695. (US government report)
  25. Martín-Sánchez E, Furukawa TA, Taylor J, et al. Systematic review and meta-analysis of cannabis treatment for chronic pain. Pain Med. 2009;10(8):1353-1368. (Systematic review and meta-analysis; 18 studies)
  26. The National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: National Academies Press; 2017. (US Government report)
  27. Huestis MA. Human cannabinoid pharmacokinetics. Chem Biodivers. 2007;4(8):1770-1804. (Review)
  28. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. (Review)
  29. Hemachandra D, McKetin R, Cherbuin N, et al. Heavy cannabis users at elevated risk of stroke: evidence from a general population survey. Aust N Z J Public Health. 2016;40(3):226-230. (Longitudinal cohort study; 7455 subjects)
  30. Mouzak A, Agathos P, Kerezoudi E, et al. Transient ischemic attack in heavy cannabis smokers--how ‘safe’ is it? Eur Neurol. 2000;44(1):42-44. (Case series; 3 patients)
  31. Singh NN, Pan Y, Muengtaweeponsa S, et al. Cannabis-related stroke: case series and review of literature. J Stroke Cerebrovasc Dis. 2012;21(7):555-560. (Literature review and case series; 14 patients)
  32. Gage SH, Hickman M, Zammit S. Association between cannabis and psychosis: epidemiologic evidence. Biol Psychiatry. 2016;79(7):549-556. (Systematic review; 10 studies)
  33. Wilkinson ST, Radhakrishnan R, D’Souza DC. Impact of cannabis use on the development of psychotic disorders. Curr Addict Rep. 2014;1(2):115-128. (Review)
  34. Manseau MW, Rajparia A, Joseph A, et al. Clinical characteristics of synthetic cannabinoid use in a large urban psychiatric emergency setting. Subst Use Misuse. 2017;52(6):822-825. (Systematic review; 110 patients)
  35. Fattore L. Synthetic cannabinoids-further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatry. 2016;79(7):539-548. (Review)
  36. Ksir C, Hart CL. Cannabis and psychosis: a critical overview of the relationship. Curr Psychiatry Rep. 2016;18(2):12. (Review)
  37. Bassir Nia A, Medrano B, Perkel C, et al. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis. J Psychopharmacol. 2016;30(12):1321-1330. (Retrospective chart review; 594 charts)
  38. Roberto AJ, Lorenzo A, Li KJ, et al. First-episode of synthetic cannabinoid-induced psychosis in a young adult, successfully managed with hospitalization and risperidone. Case Reports in Psychiatry. 2016. ID 7257489. (Case report; 1 patient)
  39. Murray RM, Quigley H, Quattrone D, et al. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195-204. (Review)
  40. Marconi A, Di Forti M, Lewis CM, et al. Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bull. 2016;42(5):1262-1269. (Meta-analysis; 10 studies; 66,816 individuals)
  41. Kalant H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(5):849-863. (Literature review)
  42. Casier I, Vanduynhoven P, Haine S, et al. Is recent cannabis use associated with acute coronary syndromes? An illustrative case series. Acta Cardiol. 2014;69(2):131-136. (Case series; 3 cases)
  43. Aronow WS, Cassidy J. Effect of marihuana and placebo-marihuana smoking on angina pectoris. N Engl J Med. 1974;291(2):65-67. (Double-blinded randomized control; 10 patients)
  44. Beaconsfield P, Ginsburg J, Rainsbury R. Marihuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med. 1972;287(5):209-212. (Double-blinded control; 9 patients)
  45. Thomas G, Kloner RA, Rezkalla S. Adverse cardiovascular, cerebrovascular, and peripheral vascular effects of marijuana inhalation: what cardiologists need to know. Am J Cardiol. 2014;113(1):187-190. (Review article)
  46. Rezkalla SH, Sharma P, Kloner RA. Coronary no-flow and ventricular tachycardia associated with habitual marijuana use. Ann Emerg Med. 2003;42(3):365-369. (Case report; 1 patient)
  47. Mathew RJ, Wilson WH, Davis R. Postural syncope after marijuana: a transcranial Doppler study of the hemodynamics. Pharmacol Biochem Behav. 2003;75(2):309-318. (Randomized double-blinded placebo-controlled study; 29 participants)
  48. Mittleman MA, Lewis RA, Maclure M, et al. Triggering myocardial infarction by marijuana. Circulation. 2001;103(23):2805-2809. (Case-crossover study; 3882 patients)
  49. lonso JV, Teo BH, Pozo FJ, et al. Brugada electrocardiogram pattern induced by cannabis; is cannabis safe? Am J Emerg Med. 2016;34(8):e1731-e1734. (Case report; 1 patient)
  50. Daccarett M, Freih M, Machado C. Acute cannabis intoxication mimicking brugada-like ST segment abnormalities. Int J Cardiol. 2007;119(2):235-236. (Case report; 1 patient)
  51. Menahem S. Cardiac asystole following cannabis (marijuana) usage--additional mechanism for sudden death? Forensic Sci Int. 2013;233(1-3):e3-e5. (Case report; 1 patient)
  52. Pratap B, Korniyenko A. Toxic effects of marijuana on the cardiovascular system. Cardiovasc Toxicol. 2012;12(2):143-148. (Case report; 1 patient)
  53. Brancheau D, Blanco J, Gholkar G, et al. Cannabis induced asystole. J Electrocardiol. 2016;49(1):15-17. (Case report; 1 patient)
  54. Von Der Haar J, Talebi S, Ghobadi F, et al. Synthetic cannabinoids and their effects on the cardiovascular system. J Emerg Med. 2016;50(2):258-262. (Case series; 2 patients)
  55. Nappe TM, Hoyte CO. Pediatric death due to myocarditis after exposure to cannabis. Clin Pract Cases Emerg Med. 2017;1(3):166-170. (Case report; 1 patient)
  56. Rodriguez-Castro CE, Alkhateeb H, Elfar A, et al. Recurrent myopericarditis as a complication of marijuana use. Am J Case Rep. 2014;15:60-62. (Case report; 1 patient)
  57. Tournebize J, Gibaja V, Puskarczyk E, et al. Myocarditis associated with cannabis use in a 15-year-old boy: a rare case report. Int J Cardiol. 2016;203:243-244. (Case report; 1 patient)
  58. Mills B, Yepes A, Nugent K. Synthetic cannabinoids. Am J Med Sci. 2015;350(1):59-62. (Review)
  59. Ribeiro LI, Ind PW. Effect of cannabis smoking on lung function and respiratory symptoms: a structured literature review. NPJ Prim Care Respir Med. 2016;26:16071. (Structured literature review; 19 articles)
  60.  Kempker JA, Honig EG, Martin GS. The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. Ann Am Thorac Soc. 2015;12(2):135-141. (Cross-sectional study; 2956 paticipants)
  61. Kazory A, Aiyer R. Synthetic marijuana and acute kidney injury: an unforeseen association. Clin Kidney J. 2013;6(3):330-333. (Case report; 1 patient)
  62. Tait RJ, Caldicott D, Mountain D, et al. A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Phila). 2016;54(1):1-13. (Systematic review; 106 studies, 4000 cases)
  63. US Centers for Disease Control and Prevention. Acute kidney injury associated with synthetic cannabinoid use--multiple states, 2012. MMWR Morb Mortal Wkly Rep. 2013;62(6):93-98. (US government report)
  64. Tournebize J, Gibaja V, Kahn JP. Acute effects of synthetic cannabinoids: update 2015. Subst Abus. 2016:1-23. (Systematic review; 46 articles, 114 patients)
  65. Adedinsewo DA, Odewole O, Todd T. Acute rhabdomyolysis following synthetic cannabinoid ingestion. N Am J Med Sci. 2016;8(6):256-258. (Case report; 1 patient)
  66. Gudsoorkar VS, Perez JA. A new differential diagnosis: synthetic cannabinoids-associated acute renal failure. Methodist Debakey Cardiovasc J. 2015;11(3):189-191. (Case report; 1 patient)
  67. Argamany JR, Reveles KR, Duhon B. Synthetic cannabinoid hyperemesis resulting in rhabdomyolysis and acute renal failure. Am J Emerg Med. 2016;34(4):e1-e2. (Case report; 1 patient)
  68. Monte AA, Calello DP, Gerona RR, et al. Characteristics and treatment of patients with clinical illness due to synthetic cannabinoid inhalation reported by medical toxicologists: a ToxIC Database study. J Med Toxicol. 2017;13(2):146-152. (Multicenter prospective cohort study; 353 cases)
  69. Shariff JA, Ahluwalia KP, Papapanou PN. Relationship between frequent recreational cannabis (marijuana and hashish) use and periodontitis in adults in the United States: National Health and Nutrition Examination Survey 2011 to 2012. J Periodontol. 2017;88(3):273-280. (Retrospective study; 1938 patients)
  70. Cairns EA, Baldridge WH, Kelly ME. The endocannabinoid system as a therapeutic target in glaucoma. Neural Plast. 2016;2016:9364091. (Review)
  71. Hanna R, Tiosano B, Dbayat N, et al. Unilateral angle-closure glaucoma with ciliochoroidal effusion after the consumption of cannabis: a case report. Case Rep Ophthalmol. 2014;5(3):439-443. (Case report; 1 patient)
  72. Trittibach P, Frueh BE, Goldblum D. Bilateral angle-closure glaucoma after combined consumption of “ecstasy” and marijuana. Am J Emerg Med. 2005;23(6):813-814. (Case report; 1 patient)
  73. Corvi F, Querques G, Lattanzio R, et al. Central retinal vein occlusion in a young patient following cannabis smoke inhalation. Eur J Ophthalmol. 2014;24(3):437-440. (Case report; 1 patient)
  74. Bajgoric S, Samra K, Chandrapalan S, et al. Cannabinoid hyperemesis syndrome: a guide for the practising clinician. BMJ Case Rep. 2015. DOI: 10.1136/bcr-2015-210246 (Case report; 1 patient)
  75. Ukaigwe A, Karmacharya P, Donato A. A gut gone to pot: a case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med. 2014:167098. (Case report; 1 patient)
  76. Sontineni SP, Chaudhary S, Sontineni V, et al. Cannabinoid hyperemesis syndrome: clinical diagnosis of an underrecognised manifestation of chronic cannabis abuse. World J Gastroenterol. 2009;15(10):1264-1266. (Case report; 1 patient)
  77. Habboushe J, Rubin A, Liu H, et al. The prevalence of cannabinoid hyperemesis syndrome among regular marijuana smokers in an urban public hospital. Basic Clin Pharmacol Toxicol. 2018;122(6):660-662. (Prevalence study; survey of 155 patients)
  78. Beech RA, Sterrett DR, Babiuk J, et al. Cannabinoid hyperemesis syndrome: a case report and literature review. J Oral Maxillofac Surg. 2015;73(10):1907-1910. (Case report; 1 patient)
  79. Hermes-Laufer J, Del Puppo L, Inan I, et al. Cannabinoid hyperemesis syndrome: a case report of cyclic severe hyperemesis and abdominal pain with long-term cannabis use. Case Rep Gastrointest Med. 2016;2016:2815901. (Case report; 1 patient)
  80. Galli JA, Sawaya RA, Friedenberg FK. Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev. 2011;4(4):241-249. (Review)
  81. Habboushe J, Sedor J. Cannabinoid hyperemesis acute renal failure: a common sequela of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2014;32(6):690.e1-e2. (Case report [1 patient] and case review [5 patients])
  82. No authors listed. Adverse effects of cannabis. Prescrire Int. 2011;20(112):18-23. (Review)
  83. Wallace EA, Andrews SE, Garmany CL, et al. Cannabinoid hyperemesis syndrome: literature review and proposed diagnosis and treatment algorithm. South Med J. 2011;104(9):659-664. (Review)
  84. Brewerton TD, Anderson O. Cannabinoid hyperemesis syndrome masquerading as an eating disorder. Int J Eat Disord. 2016;49(8):826-829. (Case report; 1 patient)
  85. Alaniz VI, Liss J, Metz TD, et al. Cannabinoid hyperemesis syndrome: a cause of refractory nausea and vomiting in pregnancy. Obstet Gynecol. 2015;125(6):1484-1486. (Case report; 1 patient)
  86. Felton D, Zitomersky N, Manzi S, et al. 13-year-old girl with recurrent, episodic, persistent vomiting: out of the pot and into the fire. Pediatrics. 2015;135(4):e1060-e1063. (Case report; 1 patient)
  87. Lavi E, Rekhtman D, Berkun Y, et al. Sudden onset unexplained encephalopathy in infants: think of cannabis intoxication. Eur J Pediatr. 2016;175(3):417-420. (Case series; 3 patients)
  88. Simonetto DA, Oxentenko AS, Herman ML, et al. Cannabinoid hyperemesis: a case series of 98 patients. Mayo Clin Proc. 2012;87(2):114-119. (Case series; 98 patients)
  89. Mastrovitch TA, Bithoney WG, DeBari VA, et al. Point-of-care testing for drugs of abuse in an urban emergency department. Ann Clin Lab Sci. 2002;32(4):383-386. (Prospective self-controlled, methods-comparison study; 170 patients)
  90. Lowe RH, Abraham TT, Darwin WD, et al. Extended urinary delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure. Drug Alcohol Depend. 2009;105(1-2):24-32. (Experimental research)
  91. Lee D, Vandrey R, Milman G, et al. Oral fluid/plasma cannabinoid ratios following controlled oral THC and smoked cannabis administration. Anal Bioanal Chem. 2013;405(23):7269-7279. (Experimental research)
  92. Namera A, Kawamura M, Nakamoto A, et al. Comprehensive review of the detection methods for synthetic cannabinoids and cathinones. Forensic Toxicol. 2015;33(2):175-194. (Review)
  93. Toennes SW, Hanisch S, Pogoda W, et al. Pitfall in cannabinoid analysis--detection of a previously unrecognized interfering compound in human serum. Anal Bioanal Chem. 2015;407(2):463-470. (Experimental research)
  94. Desjardins N, Stheneur C. [Cannabinoid hyperemesis syndrome: a review of the literature]. Arch Pediatr. 2016;23(6):619-623. (Literature review)
  95. Hickey JL, Witsil JC, Mycyk MB. Haloperidol for treatment of cannabinoid hyperemesis syndrome. Am J Emerg Med. 2013;31(6):1003.e1005-e1006. (Case report; 1 patient)
  96. Witsil JC, Mycyk MB. Haloperidol, a novel treatment for cannabinoid hyperemesis syndrome. Am J Ther. 2017;24(1):e64-e67. (Retrospective chart review; 4 cases)
  97. Richards JR, Gordon BK, Danielson AR, et al. Pharmacologic treatment of cannabinoid hyperemesis syndrome: a systematic review. Pharmacotherapy. 2017;37(6):725-734. (Systematic review; 63 studies)
  98. Sorensen CJ, DeSanto K, Borgelt L, et al. Cannabinoid hyperemesis syndrome: diagnosis, pathophysiology, and treatment-a systematic review. J Med Toxicol. 2017;13(1):71-87. (Systematic review; 183 studies)
  99. Müller HH, Kornhuber J, Sperling W. The behavioral profile of Spice and synthetic cannabinoids in humans. Brain Res Bull. 2016;126(Pt 1):3-7. (Review)
  100. Dezieck L, Hafez Z, Conicella A, et al. Resolution of cannabis hyperemesis syndrome with topical capsaicin in the emergency department: a case series. Clin Toxicol (Phila). 2017:1-6. (Case series; 13 patients)
  101. Fernandes ES, Fernandes MA, Keeble JE. The functions of TRPA1 and TRPV1: moving away from sensory nerves. Br J Pharmacol. 2012;166(2):510-521. (Review)
  102. Gunderson EW, Haughey HM, Ait-Daoud N, et al. “Spice” and “K2” herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans. Am J Addict. 2012;21(4):320-326. (Case series and systematic review; 9 articles, 3 patients)
  103. Jones JL, Abernathy KE. Successful treatment of suspected cannabinoid hyperemesis syndrome using haloperidol in the outpatient setting. Case Rep Psychiatry. 2016;2016:3614053. (Case report; 1 patient)
  104. Román F, Llorens P, Burillo-Putze G. [Topical capsaicin cream in the treatment for cannabinoid hyperemesis syndrome]. Med Clin (Barc). 2016;147(11):517-518. (Literature review and case report; 1 patient)
  105. Center for Behavioral Health Statistics and Quality. Emergency department visits involving marijuana among adolescents aged 15-70: increase from 2005 to 2010 varied by gender. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012. (US Government report)
  106. Besli GE, Ikiz MA, Yildirim S, et al. Synthetic cannabinoid abuse in adolescents: a case series. J Emerg Med. 2015;49(5):644-650. (Case series; 16 cases)
  107. Cohen J, Morrison S, Greenberg J, et al. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics. 2012;129(4):e1064-e1067. (Case series; 3 cases)
  108. Louis M, Ricketson J, Wishart I. What is the accuracy of screening instruments for alcohol and cannabis misuse disorders among adolescents and young adults in the emergency department? Ann Emerg Med. 2013;61(4):404-406. (Systematic review; 6 studies)
  109. Castellanos D, Gralnik LM. Synthetic cannabinoids 2015: an update for pediatricians in clinical practice. World J Clin Pediatr. 2016;5(1):16-24. (Review article)
  110. Clark BC, Georgekutty J, Berul CI. Myocardial ischemia secondary to synthetic cannabinoid (K2) use in pediatric patients. J Pediatr. 2015;167(3):757-761.e1. (Case series; 8 patients)
  111. McKeever RG, Vearrier D, Jacobs D, et al. K2--not the spice of life; synthetic cannabinoids and ST elevation myocardial infarction: a case report. J Med Toxicol. 2015;11(1):129-131. (Case report; 1 patient)
  112. Hamilton RJ, Keyfes V, Banka SS. Synthetic cannabinoid abuse resulting in ST-segment elevation myocardial infarction requiring percutaneous coronary intervention. J Emerg Med. 2017;52(4):496-498. (Case report; 1 patient)
  113. McIlroy G, Ford L, Khan JM. Acute myocardial infarction, associated with the use of a synthetic adamantyl-cannabinoid: a case report. BMC Pharmacol Toxicol. 2016;17:2. (Case report; 1 patient)
  114. Andrews KH, Bracero LA. Cannabinoid hyperemesis syndrome during pregnancy: a case report. J Reprod Med. 2015;60(9-10):430-432. (Case report; 1 patient)
  115. Roberson EK, Patrick WK, Hurwitz EL. Marijuana use and maternal experiences of severe nausea during pregnancy in Hawai’i. Hawaii J Med Public Health. 2014;73(9):283-287. (Retrospective study; 4735 participants)
  116. Schmid SM, Lapaire O, Huang DJ, et al. Cannabinoid hyperemesis syndrome: an underreported entity causing nausea and vomiting of pregnancy. Arch Gynecol Obstet. 2011;284(5):1095-1097. (Case report; 1 patient)
  117. Hayatbakhsh MR, Flenady VJ, Gibbons KS, et al. Birth outcomes associated with cannabis use before and during pregnancy. Pediatr Res. 2012;71(2):215-219. (Chart review; 24,874 charts)
  118. Gunn JK, Rosales CB, Center KE, et al. Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. BMJ Open. 2016;6(4):e009986. (Systematic review and meta-analysis; 24 studies)
  119. Unimed Pharmaceutical Inc. Marinol. 2002; NDA 18-651/S-018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/018651s018lbl.pdf. Accessed July 10, 2018. (FDA New Drug Application)
  120. Valeant Pharmaceuticals International. Cesamet. 2009; NDA 18-677/S-011. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/018677s011lbl.pdf. Accessed July 10, 2018. (FDA New Drug Application)
  121. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs R D. 2003;4(5):306-309. (Review)
  122. GW Pharmaceuticals. Sativex® (delta-9-tetrahydrocannibinol and cannabidiol in the EU) (nabiximols in the USA). Available at: https://www.gwpharm.com/products-pipeline/sativex. Accessed July 10, 2018. (Drug company website)
  123. Joseph J, Wang S, Lee J, et al. Carboxyl-terminal domain of transient receptor potential vanilloid 1 contains distinct segments differentially involved in capsaicin- and heat-induced desensitization. J Biol Chem. 2013;288(50):35690-35702. (Experimental research)
  124. Cerdá M, Wall M, Keyes KM, et al. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2012;120(1-3):22-27. (Cross-sectional (national survey) study; approximately 68,000 individuals)

 

  CME Information

Accreditation: EB Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the ACCME.

Credit Designation: EB Medicine designates this enduring material for a maximum of 4 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Specialty CME: Included as part of the 4 credits, this CME activity is eligible for 1 Behavioral credit and 2 Pharmacology credits in pharmacotherapy, subject to your state and institutional approval.

Faculty Disclosures: It is the policy of EB Medicine to ensure objectivity, balance, independence, transparency, and scientific rigor in all CME-sponsored educational activities. All faculty participating in the planning or implementation of a sponsored activity are expected to disclose to the audience any relevant financial relationships and to assist in resolving any conflict of interest that may arise from the relationship. In compliance with all ACCME Essentials, Standards, and Guidelines, all faculty for this CME activity were asked to complete a full disclosure statement. The information received is as follows: Dr. Williams, Dr. Shaukat, Dr. Mishler, Dr. Toscano, and their related parties report no significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) discussed in this educational presentation. Dr. Habboushe made the following disclosure: MD Aware LLC (d/b/a MDCalc), cofounder, CEO, part owner; and Dr. Jagoda made the following disclosures: Consultant, Daiichi Sankyo Inc; Consultant, Pfizer Inc; Consultant, Banyan Biomarkers Inc; Consulting fees, EB Medicine.

Commercial Support: This issue of Emergency Medicine Practice did not receive any commercial support.

  Related Links

To view this issue, please choose one of the options below:

Purchase a
subscription
$349
Emergency Medicine Practice
 
Purchase issue and
CME test (4 credits)
$39
Emergency Medicine Practice
single issue
Sign up for a free trial
Free 48-hour trial
Emergency Medicine Practice
 

ACEP18, EB Medicine CME Discount Sale

 
About EB Medicine:
Products:
Accredited By:
ACCME ACCME
AMA AMA
ACEP ACEP
AAFP AAFP
AOA AOA
AAP AAP
Endorsed By:
AEMAA AEMAA
HONcode HONcode
STM STM

 

Last Modified: 10/23/2018
© EB Medicine